Kaerus Bioscience secures orphan drug designation for fragile x syndrome treatment
14th May 2025 Uncategorised 0
FDA recognises KER-0193 as a potential therapy for rare paediatric disease

More: Kaerus Bioscience secures orphan drug designation for fragile x syndrome treatment
Source: News
